For Informed People Using Alternative Treatments
Comments
-
Flaviarose, Welcome, and congrats to you for taking charge of your health. Thanks so much for the tip on melatonin. I am going to look into that myself. B17 is interesting too. I think that we have every right and reason to seek whatever tx we can find, esp. to treat aggressive types of cancer. I'm posting these articles/studies just in case you haven't seen this research. One mentioned that GLA had synergistic effects w/ Herceptin. Wishing you all good. God speed.
“Walk on with hope in your heart,
and you'll never walk alone”
http://www.news-medical.net/news/2005/11/03/14257.aspx
http://www.eurekalert.org/pub_releases/2005-11/nu-poc102705.php
http://www.dailymail.co.uk/health/article-367355/Evening-primrose-oil-help-beat-breast-cancer.html -
wow, Lifeandwind, this is potentially life altering information. I take a boat load of supplements, but not GLA. I've copied one of those articles and sent to my oncologist. I wish I had known about this when I first started chemo! thank you so much for this information!!!!!! -
delete
-
Sunflowers - not a typo - it is 125 milligrams.
Lenn13ka - that book sounds very interesting! I'm going to check my library first to see if they have it.
crabbiepattie - I was pretty amazed myself! I really think it is the selenium - which most thyroid pts and especially autoimmune are deficient in - along with the iodine protocol. I did the gluten-free thing for a while, and even did dairy, egg, and nut free as well, and the markers barely budged. Gluten free only got them down to the 400s and they stuck in that range for a long time, telling me there was still inflammation going on. I felt soooo sluggish and puffy - very hypothyroid. Once I started the selenium and iodine (plus all the companion supplements), they started dropping FAST and my metabolism started improving. I lowered my thyroid dose on my own to almost nothing now and I can eat as much as I want and I stay the same weight. Lost fat all over and am very lean now. And no, I am not hyperthyroid now! Just finally healthy!
RE: NAC - here's another voice on the subject - I may have talked myself out of it now. -
Forgot to add:
Flaviarose - doesn't 20 mg of melatonin put you in a coma?? I take 5 right before bed and I'm out like a light. Was that the recommendation from your nutritionist?
Sunflowers - I believe the recommended dose for thyroid pts (as I rambled on about above) is 400 mcg (have to check my bottle). I take 5000 units of D3 and my last level was 75. My oncologist was thrilled at that. She has autoimmune disease as well (lupus) and we chat a lot about supplements, exercise, diet, etc. Nice that she is so attuned to that. -
Melatonin knocks me out too! Are you ladies taking it for more than sleep purposes? Strangely I sleep better with 2.5 mg (I cut my 5 mg in half) of Ambien but try not to take that more than once per week. I usually take Calms Forte by Hylands if my mind is racing too much to sleep.
I am so excited to find so many new ideas to research ladies! I see my oncologist on Monday to discuss my treatment plan now that I have had surgery so I may find a few more things to bring with to discussJust on a side note - is anyone here BRCA positive???
-
delete
-
Yes! 400mcg of selenium daily....also, that amount has been shown as a cancer fighter as well as a companion nutrient to iodine. I take 20mg of melatonin nightly as well...I take the chewables as that is supposed to absorb the best but I am interested in time release...anyone take time release?
-
@light....Are you triple negative? Just asking as you had posted NAC effective for triple negative.
-
melatonin is something I take every night too, 5mg. I hope it's alright to ask, but how do you take 20 mg? I too would be in a coma! -
Here is a short article we have on Melatonin... may be helpful. -
a friend of mine said her nutritionist recommends eating a few Brazil nuts daily to get necessary selenium. Does anyone here use Brazil nuts for this purpose? Any idea what the recommended serving size would be for proper dosage? -
I take two brazil nuts a day, and it is suppose to be about 200 mg. -
You're welcome flaviarose! I have had those studies saved for a long time, very glad to finally share them here.
Thanks mods for that article on melatonin. I have yet to do my research on that one. Really glad to hear this, as well as the reminder regarding recommended dosage.
Jojo, I am ER+ PR+HER2 Negative. Just sometimes come across articles that might be of use to someone else.
Sunflowers, really understand what you mean about the frustration with trying to find the right and safe protocols. Always good to dig deeper before making any decisions about anything. Here's some important info in relation to selenium and breast cancer. One of these indicated that cancer can promote low selenium in the body, or more accurately that low selenium is a consequence of the cancer. Brewers yeast and nuts both contain selenium.
http://www.ncbi.nlm.nih.gov/pubmed/22736377
http://www.ncbi.nlm.nih.gov/pubmed/19352569
http://www.canceractive.com/cancer-active-page-link.aspx?n=518 -
and a (very) short article on selenium: -
Wow, interesting studies about low selenium and cancer (or as a consequence of cancer). I wonder if the anti-cancer benefit of white button mushrooms is because of their high selenium content? -
I take upwards of 800 mg of selenium daily.
-
Actually, I think I recall reading that white button mushrooms acted as natural aromatase inhibitors. And if they are also good sources of selenium (and anti-inflammatory) I should be eating them more often! -
You ladies keep adding to my research pile! Now off to research selenium... -
kayb,
Ditto on the song but I was afraid to say it since it's ot. -
Re: melatonin, yes recommended by nutritionist 20-50 mg. 20 mg. doesn't make me comatose, I'm still a bad sleeper. Here is the information she sent me: And melatonin
1. Evid Based Complement Alternat Med. 2013;2013:879746. doi: 10.1155/2013/879746. Epub 2013 Apr 7.
Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells.
Jung JH, Sohn EJ, Shin EA, Lee D, Kim B, Jung DB, Kim JH, Yun M, Lee HJ, Park YK, Kim SH.
College of Oriental Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea.
Since the dysregulation of ribosome biogenesis is closely associated with tumor progression, in the current study, the critical role of ribosome biogenesis related signaling was investigated in melatonin and/or puromycin induced apoptosis in MDA-MB-231 breast cancer cells. Despite its weak cytotoxicity, melatonin from 3 mM attenuated the expression of 45S pre-ribosomal RNA (pre-rRNA), UBF as a nucleolar transcription factor, and fibrillarin at mRNA level and consistently downregulated nucleolar proteins such as UBF and fibrillarin at protein level in MDA-MB-231 cells. Furthermore, immunofluorescence assay revealed that UBF was also degraded by melatonin in MDA-MB- 231 cells. In contrast, melatonin attenuated the expression of survival genes such as Bcl- xL, Mcl-1, cyclinD1, and cyclin E, suppressed the phosphorylation of AKT, mTOR, and STAT3, and cleaved PARP and activated caspase 3 only at a high concentration of 12?mM. However, combined treatment of melatonin (3?mM) and puromycin (1?μM) synergistically inhibited viability, attenuated the expression of 45S pre-rRNA and UBF, and consistently downregulated UBF, XPO1 and IPO7, procaspase 3, and Bcl-xL in MDA-MB 231 cells. Overall, these findings suggest that melatonin can be a cancer preventive agent by combination with puromycin via the inhibition of 45S pre-rRNA and UBF in MDA-MB 231 breast cancer cells.
PMCID: PMC3638601 PMID: 23690862 [PubMed - in process]
2. Oncol Rep. 2013 May;29(5):2058-64. doi: 10.3892/or.2013.2314. Epub 2013 Feb 28.
Melatonin modulates aromatase activity and expression in endothelial cells.
Alvarez-García V, González A, Martínez-Campa C, Alonso-González C, Cos S.
Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, 39011 Santander, Spain.
Melatonin is known to suppress the development of endocrine-responsive breast cancers by interacting with the estrogen signaling pathways. Paracrine interactions between malignant epithelial cells and proximal stromal cells are responsible for local estrogen biosynthesis. In human breast cancer cells and peritumoral adipose tissue, melatonin downregulates aromatase, which transforms androgens into estrogens. The presence of aromatase on endothelial cells indicates that endothelial cells may contribute to tumor growth by producing estrogens. Since human umbilical vein endothelial cells (HUVECs) express both aromatase and melatonin receptors, the aim of the present study was to evaluate the ability of melatonin to regulate the activity and expression of aromatase on endothelial cells, thus, modulating local estrogen biosynthesis. In the present study, we demonstrated that melatonin inhibits the growth of HUVECs and reduces the local
biosynthesis of estrogens through the downregulation of aromatase. These results are supported by three lines of evidence. Firstly, 1 mM of melatonin counteracted the testosterone-induced cell proliferation of HUVECs, which is dependent on the local biosynthesis of estrogens from testosterone by the aromatase activity of the cells. Secondly, we found that 1 mM of melatonin reduced the aromatase activity of HUVECs. Finally, by real-time RT-PCR, we demonstrated that melatonin significantly downregulated the expression of aromatase as well as its endothelial-specific aromatase promoter region I.7. We conclude that melatonin inhibits aromatase activity and expression in HUVECs by regulating gene expression of specific aromatase promoter regions, thereby reducing the local production of estrogens.
PMID: 23450505 [PubMed - in process]
3. BMC Cell Biol. 2013 Jan 7;14:1. doi: 10.1186/1471-2121-14-1.
Melatonin enhances DNA repair capacity possibly by affecting genes involved in DNA damage responsive pathways.
Liu R, Fu A, Hoffman AE, Zheng T, Zhu Y.
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China.
BACKGROUND: Melatonin, a hormone-like substance involved in the regulation of the circadian rhythm, has been demonstrated to protect cells against oxidative DNA damage and to inhibit tumorigenesis. RESULTS: In the current study, we investigated the effect of melatonin on DNA strand breaks using the alkaline DNA comet assay in breast cancer (MCF-7) and colon cancer (HCT-15) cell lines. Our results demonstrated that cells pretreated with melatonin had significantly shorter Olive tail moments compared to non- melatonin treated cells upon mutagen (methyl methanesulfonate, MMS) exposure, indicating an increased DNA repair capacity after melatonin treatment. We further examined the genome-wide gene expression in melatonin pretreated MCF-7 cells upon carcinogen exposure and detected altered expression of many genes involved in multiple DNA damage responsive pathways. Genes exhibiting altered expression were further analyzed for functional interrelatedness using network- and pathway-based bioinformatics analysis. The top functional network was defined as having relevance for "DNA Replication, Recombination, and Repair, Gene Expression, [and] Cancer". CONCLUSIONS: These findings suggest that melatonin may enhance DNA repair capacity by affecting several key genes involved in DNA damage responsive pathways.
PMCID: PMC3543845 PMID: 23294620 [PubMed - in process]
4. J Pineal Res. 2012 Aug 16. doi: 10.1111/jpi.12007. [Epub ahead of print]
Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells.
Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S.
Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain.
Melatonin exerts oncostatic effects on breast cancer by interfering with the estrogen- signaling pathways. Melatonin reduces estrogen biosynthesis in human breast cancer cells, surrounding fibroblasts and peritumoral endothelial cells by regulating cytokines that influence tumor microenvironment. This hormone also exerts antiangiogenic activity in tumoral tissue. In this work, our objective was to study the role of melatonin on the regulation of the vascular endothelial growth factor (VEGF) in breast cancer cells. To accomplish this, we cocultured human breast cancer cells (MCF-7) with human umbilical vein endothelial cells (HUVECs). VEGF added to the cultures stimulated the proliferation of HUVECs and melatonin (1 mm) counteracted this effect. Melatonin reduced VEGF production and VEGF mRNA expression in MCF-7 cells. MCF-7 cells cocultured with HUVECs stimulated the endothelial cells proliferation and increased VEGF levels in the culture media. Melatonin counteracted both stimulatory effects on HUVECs proliferation and on VEGF protein levels in the coculture media. Conditioned media from MCF-7 cells increased HUVECs proliferation, and this effect was significantly counteracted by anti- VEGF and 1 mm melatonin. All these findings suggest that melatonin may play a role in the paracrine interactions between malignant epithelial cells and proximal endothelial cells through a downregulatory action on VEGF expression in human breast cancer cells, which decrease the levels of VEGF around endothelial cells. Lower levels of VEGF could be important in reducing the number of estrogen-producing cells proximal to malignant cells as well as decreasing tumoral angiogenesis.
© 2012 John Wiley & Sons A/S.
PMID: 23013414 [PubMed - as supplied by publisher]
5. Cell Mol Life Sci. 2013 Jun;70(12):2139-2157. Epub 2012 Sep 25. Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Proietti S, Cucina A, Reiter RJ, Bizzarri M.
Department of Clinical and Molecular Medicine, University "La Sapienza", Rome, Italy.
Melatonin is involved in many physiological functions and it plays an important role in many pathological processes as well. Melatonin has been shown to reduce the incidence of experimentally induced cancers and can significantly inhibit the growth of some human tumors, namely hormone-dependent cancers. The anticancer effects of melatonin have been observed in breast cancer, both in in vivo with models of chemically induced rat mammary tumors, and in vitro studies on human breast cancer cell lines. Melatonin acts at different physiological levels and its antitumoral properties are supported by a set of complex, different mechanisms of action, involving apoptosis activation, inhibition of proliferation, and cell differentiation.
PMID: 23007844 [PubMed - as supplied by publisher]
6. J Pineal Res. 2012 Jun 27. doi: 10.1111/j.1600-079X.2012.01027.x. [Epub ahead of print]
Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin.
Lee SE, Kim SJ, Yoon HJ, Yu SY, Yang H, Jeong SI, Hwang SY, Park CS, Park YS. Department of Microbiology, School of Medicine, Kyung Hee University, Seoul, Korea.
Epigenetic alterations have emerged as an important mechanism involved in tumorigenesis. The epigenetic impact of DNA methylation in various types of human cancer is not completely understood. Previously, we observed melatonin-induced differential expression of miRNA and miRNA-related genes in human breast cancer cell lines that indicated an anticancer effect of melatonin. In this report, we further characterized epigenetic changes in melatonin-exposed MCF-7 cells through the analysis of DNA methylation profiles in breast cancer cells to provide new insights into the potential mechanisms of the anticancer effect of melatonin. Microarray-based DNA methylation and gene expression profiling were carried out using human breast cancer cell lines. We further identified a number of mRNAs whose expression levels show an inverse correlation with DNA methylation levels. The mRNA expression levels and methylation status of candidate genes in melatonin-exposed cells were confirmed by real-time quantitative PCR and bisulfite PCR. This approach led to the detection of cancer-related genes, which were oncogenic genes, including EGR3 and POU4F2/Brn-3b were down-regulated, while the tumor suppressor gene, GPC3, was up-regulated by 1 nm melatonin-treated MCF-7 cells. Our results provide detailed insights into the DNA methylation patterns induced by melatonin and suggest a
potential mechanism of the anticancer effect of aberrant DNA methylation in melatonin- treated breast cancer cells.
© 2012 John Wiley & Sons A/S.
PMID: 22856590 [PubMed - as supplied by publisher]
7. Expert Opin Investig Drugs. 2012 Jun;21(6):819-31. doi: 10.1517/13543784.2012.681045. Epub 2012 Apr 16.
Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation.
Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ.
University of Cantabria, Department of Physiology & Pharmacology, 39011 Santander, Spain. barcelo@unican.es
INTRODUCTION: The possible oncostatic properties of melatonin on different types of neoplasias have been studied especially in hormone-dependent adenocarcinomas. Despite the promising results of these experimental investigations, the use of melatonin in breast cancer treatment in humans is still uncommon. AREAS COVERED: This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo- or radiotherapy. EXPERT OPINION: The clinical utility of melatonin depends on the appropriate identification of its actions. Because of its SERM (selective estrogen receptor modulators) and SEEM (selective estrogen enzyme modulators) properties, and its virtual absence of contraindications, melatonin could be an excellent adjuvant with the drugs currently used for breast cancer prevention (antiestrogens and antiaromatases). The antioxidant actions also make melatonin a suitable treatment to reduce oxidative stress associated with chemotherapy, especially with anthracyclines, and radiotherapy.
PMID: 22500582 [PubMed - indexed for MEDLINE]
8. Breast Cancer Res Treat. 2012 Apr;132(2):765-71. doi: 10.1007/s10549-012-1953-4. Epub 2012 Jan 12.
Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts.
Knower KC, To SQ, Takagi K, Miki Y, Sasano H, Simpson ER, Clyne CD.
Cancer Drug Discovery Laboratory, Prince Henry's Institute of Medical Research, PO Box 5152, Clayton, VIC 3168, Australia. kevin.knower@princehenrys.org
The main biological active substance secreted by the pineal gland, melatonin (MLT), counteracts the effects of estrogens in breast cancer via exerting a number of its own oncostatic properties. Recent studies of postmenopausal women have identified that the major metabolite of MLT is statistically significantly associated with a lower risk of developing breast cancer. While MLT production decreases with age, breast cancer risk, however, increases with age and obesity. We hypothesize that MLT inhibits estrogen production in breast adipose fibroblasts (BAFs), the main local source of estrogen in breast tumors of postmenopausal women, by inhibiting transcription of the CYP19A1 gene that encodes the key enzyme aromatase. Normal BAFs were cultured from women undergoing breast reduction surgery, while breast cancer-associated fibroblasts (CAFs) were isolated from three women with estrogen receptor (ER) positive invasive ductal carcinomas. MTNR1A and MTNR1B receptor expression and CYP19A1 mRNA expression following MLT treatments were determined by qRT-PCR. BAFs express the G-protein coupled MLT receptors MTNR1A and MTNR1B with elevated levels of MTNR1A found in CAFs. Treatment of BAFs and CAFs with MLT resulted in significant suppression of CYP19A1 transcription and aromatase activity at pharmacological, physiological and sub- physiological concentrations. MLT suppression occurred through promoter-specific PI.4-, PI.3- and PII-derived CYP19A1 mRNA. Stimulation of CYP19A1 PII-mRNA and aromatase activity by prostaglandin E(2) (PGE(2)) were significantly attenuated by physiological doses of MLT. Lower levels of MLT in aging women may increase the risk of progressing ER- positive breast cancer through a decreased ability to suppress CYP19A1 expression and subsequent local estrogen production in BAFs/CAFs.
PMID: 22237979 [PubMed - indexed for MEDLINE]
9. J Pineal Res. 2012 Apr;52(3):282-90. doi: 10.1111/j.1600-079X.2011.00940.x. Epub 2011 Dec 12.
Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production.
Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S.
Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain.
Melatonin exerts oncostatic effects on breast cancer by interfering with the estrogen signaling pathways. Melatonin inhibits aromatase enzyme in breast cancer cells and fibroblasts. In addition, melatonin stimulates the adipogenic differentiation of fibroblasts. Our objective was to study whether melatonin interferes in the desmoplastic reaction by regulating some factors secreted by malignant cells, tumor necrosis factor (TNF)-a, interleukin (IL)-11, and interleukin (IL)-6. To accomplish this, we co-cultured 3T3-L1 cells with MCF-7 cells. The addition of breast cancer cells to the co-cultures inhibited the differentiation of 3T3-L1 preadipocytes to mature adipocytes, by reducing the intracytoplasmic triglyceride accumulation, an indicator of adipogenic differentiation, and also stimulated their aromatase activity. Melatonin counteracted the inhibitory effect on adipocyte differentiation and aromatase activity induced by MCF-7 cells in 3T3-L1 cells. The levels of cytokines in the co-culture media were 10 times those found in culture of 3T3-L1 cells alone. Melatonin decreased the concentrations of cytokines in the media and counteracted the stimulatory effect induced by MCF-7 cells on the cytokine levels. One millimolar melatonin induced a reduction in TNF-a, IL-6, and IL-11 mRNA expression in MCF-7 and 3T3-L1 cells. The findings suggest that melatonin may play a role in the desmoplastic reaction in breast cancer through a downregulatory action on the expression of antiadipogenic cytokines, which decrease the levels of these cytokines. Lower levels of cytokines stimulate the differentiation of fibroblasts and decrease both aromatase activity and expression, thereby reducing the number of estrogen-producing cells proximal to malignant cells.
© 2011 John Wiley & Sons A/S.
PMID: 22151118 [PubMed - indexed for MEDLINE]
10. Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):109-23.
Melatonin, immune function and cancer.
Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP.
Sri Sathya Sai Medical Educational and Research Foundation, Prasanthi Nilayam, 40-Kovai Thirunagar Coimbatore-641014, India. sainivasan@yahoo.com
Melatonin is a natural substance ubiquitous in distribution and present in almost all species ranging from unicellular organisms to humans. In mammals, melatonin is synthesized not only in the pineal gland but also in many other parts of the body, including the eyes, bone
marrow, gastrointestinal tract, skin and lymphocytes. Melatonin influences almost every cell and can be traced in membrane, cytoplasmic, mitochondrial and nuclear compartments of the cell. The decline in the production of melatonin with age has been suggested as one of the major contributors to immunosenescence and development of neoplastic diseases. Melatonin is a natural antioxidant with immunoenhancing properties. T-helper cells play an important role for protection against malignancy and melatonin has been shown to enhance T-helper cell response by releasing interleukin-2, interleukin-10 and interferon-?. Melatonin is effective in suppressing neoplastic growth in a variety of tumors like melanoma, breast and prostate cancer, and ovarian and colorectal cancer. As an adjuvant therapy, melatonin can be beneficial in treating patients suffering from breast cancer, hepatocellular carcinoma or melanoma. In this paper, a brief review of recent patents on melatonin and cancer has also been presented.
PMID: 22074586 [PubMed - indexed for MEDLINE] -
do you take the 20 mg at once? -
re: time release - my nutritionist said no. She also said to take it at exactly the same time every night, even if you go to bed at different times - it regulates your circadian rhythm. -
yes, I take 20 mg. at 10 pm. I also take zyflammend PM and ativan, and still have trouble falling asleep!!! -
delete
-
Chuckling here....the thought of 2 Brazil nuts. Kind of reminds me of the time I heard a person refer to "an Oreo" - never heard it spoken of in the singularWell, I guess the Brazil nuts are pretty large, but I know they'd be too tempting to have around me. I do have raw almonds, but that's about the only "safe" one for me. Thank goodness macadamia nuts are so expensive.
-
Hi All,
I also take 20 mg of melatonin every night - I get 20 mg capsules from my nautrapathic.
I also take numerous other supplements including mushroom capsules and tincture: Fungi Perfect Host Defense and Turkey Tail.
-
i am starting to look into alternative but am overwhelmed by all of the information. I am also concerned with conflicting information. I will think i finally have something down and read negative reports on something and start to doubt.
I completed one chemo treatment and developed diverticulitis and decided to withdraw from chemo. Because i am triple neg i think i will have to be vigilent and so will come here to learn what i can.
I appreciate all of the knowledge and time taken to share. -
I hear you,Wrenn, there is so much conflicting information out there. My nutritionist put me on NAC - and now I've learned that might not be so good.... of course, a disclaimer, I consulted with the nutritionist in May, and she put me on a protocol for during chemo and radiation. I will consult with her in January after I have some blood work from my PCP and see how she would alter the protocol. She is very very knowledgeable, but no one can know everything, and new stuff is coming out all the time. when I had anemia and eye twitching and heart palpitations from the chemo she recommended taurine and arginine - I had just read how arginine might promote angiogenesis - and she said - don't take it then. I wonder if I consult with her in Jan. if she will take me off NAC. I read Dr. Russell Blaylock's Natural Strategies for Cancer Patients, and he put people on NAC because it would be protective of the kidneys during chemo.
My own opinion - that there are some supplements that you will take for a while - and there are some that you will take all the time. And it will change.
In terms of Vit. D., my level was 46 taking 5000 IU a day. I was taking a life extension product with Vit. K and iodine. You need to balance your D with K. Nutritionist didn't like the life extension Vit D. because it was dry, not an oily capsule. She has done a lot of research on Vit. D. I learned of her from a friend who learned of her on the Mercola website - she did an interview discussing Vit. D. because she is one of the premier researchers on it. Here name is Krispin Sullivan and she is referenced here: http://articles.mercola.com/sites/articles/archive/2002/02/23/vitamin-d-part-five.aspx. I'm now on cod liver oil, which she says would be enough for someone who lived where they get sun all year. Since I live in Massachusetts I supposedly don't make Vit D. from about Sept - April.... and would usually be pretty covered up anyway.... she said the recommended dose for me would be 1000. I don't think that is enough, which is why I am anxious to see my blood work in January. She also says that too much Vit D can be as bad as too little, and she thinks my level was fine at 46. I personally would like to see it higher.
Is anyone doing pancreatic enzymes? -
Welcome Wrenn!
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team